Can molecular tests be run on the same sample used for cytology?

Often yes; liquid-based cytology preparations retain residual cells and fluid from which nucleic acids can be extracted, allowing HPV detection or other molecular assays on the same specimen.

Why is HPV testing used in cervical cancer screening?

Persistent infection with high-risk HPV types is the necessary cause of nearly all cervical cancers, so detecting viral nucleic acid identifies the population at risk and complements or, in some programmes, precedes morphologic cytology.

Molecular Testing and HPV Detection on Cytologic Specimens

Molecular testing on cytologic specimens applies nucleic-acid-based assays to cells obtained by exfoliation or aspiration, detecting DNA or RNA targets that reveal infection, mutations, or other clinically relevant alterations. The detection of high-risk human papillomavirus (HPV) on cervical cytology samples is the most widespread example, while sequencing of fine-needle aspirates extends molecular diagnosis to solid tumours.

Definition

Molecular testing on cytologic specimens is the application of nucleic-acid-based assays - including viral nucleic-acid detection and tumour mutation profiling - to cells obtained by exfoliative or aspiration cytology or to their residual liquid-based material.

Scope

The entry covers the use of cytologic and liquid-based residual material as a source of nucleic acids, HPV detection in cervical screening, and broader molecular assays such as next-generation sequencing on aspirates. It is a methodological and reference overview and does not provide screening protocols or treatment guidance.

Core questions

What pre-analytic factors determine whether cytologic material yields adequate nucleic acid for testing?
How does high-risk HPV detection complement morphologic cervical cytology in screening?
Which molecular assays can be performed on fine-needle aspirate and residual cytology material?

Key concepts

Nucleic-acid extraction from cytologic material
High-risk HPV detection
Liquid-based cytology as a molecular substrate
Reflex and co-testing strategies
Next-generation sequencing on aspirates
Specimen adequacy for molecular assays

Mechanisms

Cytologic samples, particularly liquid-based preparations, retain cells and residual fluid from which DNA and RNA can be extracted; these nucleic acids are then interrogated by amplification, hybridization, or sequencing assays. In cervical applications, assays detect the DNA or RNA of high-risk HPV types whose persistent infection underlies cervical carcinogenesis, and such testing can be combined with or substituted for morphologic cytology. In solid-tumour cytology, fine-needle aspirate material can supply sufficient nucleic acid for targeted or next-generation sequencing to identify diagnostically or therapeutically relevant alterations.

Clinical relevance

Molecular testing turns a cytologic sample into a source of genomic and viral information used in classification, risk stratification, and biomarker reporting; HPV detection in particular has reshaped cervical screening paradigms. This entry describes how such testing is performed; specific screening algorithms and biomarker-based decisions are clinical matters and are not individualized advice here.

Epidemiology

Persistent infection with high-risk HPV types is the necessary cause of nearly all cervical cancers, which makes detection of viral nucleic acid on cervical cytology specimens a biologically grounded screening target (Schiffman et al., 2007).

Evidence & guidelines

Randomized screening evidence, including end-of-study results from the ATHENA study, has evaluated primary HPV testing as a first-line cervical screening strategy compared with cytology-based approaches (Wright et al., 2015). For solid tumours, studies have shown that next-generation sequencing can be performed on fine-needle aspirate cytology specimens to obtain molecular diagnoses (Qiu et al., 2015).

History

The discovery that high-risk HPV is the necessary cause of cervical cancer transformed cervical cytology from a purely morphologic screen into a setting for molecular co-testing and, later, primary HPV screening. In parallel, the growth of targeted cancer therapy drove adaptation of molecular and sequencing assays to the small samples produced by fine-needle aspiration.

Debates

Should primary HPV testing replace cytology-based cervical screening?: Trials such as ATHENA support primary HPV testing as a first-line screen, but the optimal combination of HPV testing, cytology, and triage continues to be debated and varies across screening programmes.

Seminal works

schiffman-2007
wright-2015

Frequently asked questions

Can molecular tests be run on the same sample used for cytology?: Often yes; liquid-based cytology preparations retain residual cells and fluid from which nucleic acids can be extracted, allowing HPV detection or other molecular assays on the same specimen.
Why is HPV testing used in cervical cancer screening?: Persistent infection with high-risk HPV types is the necessary cause of nearly all cervical cancers, so detecting viral nucleic acid identifies the population at risk and complements or, in some programmes, precedes morphologic cytology.